NCT07711002 · Interventional trial
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Overall registry status Recruiting
Phase 3
Conditions Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Delaware Valley sites
- Research Site · Camden, NJ · Camden County · Not yet recruiting
First posted
Registry updated
Added to the directory